7.140USD-11.63%Mkt Cap: 187.43M USDP/E: —Last update: 2026-05-26
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a la…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap187.43M USD
Enterprise Value149.95M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.55M USD
Revenue/Share—
Last Price7.140 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.16
PEG—
EV/EBITDA-5.01
EV/Revenue—
P/S—
P/B5.11
EPS (TTM)-2.25
EPS (Forward)6.56
52W Range
3.71047% of range11.00
52W High11.00 USD
52W Low3.710 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.94%
ROA-54.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.32M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield-3.79%
Net Debt-53.77M USD
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity0.01
Current Ratio2.40
Quick Ratio2.06
Book Value/Sh1.494 USD
Cash/Share2.044 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 20, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)40.99 USD
Target Range15.00 USD – 90.00 USD
# Analysts10
Ownership
Shares Out.26.70M
Float24.28M
Insiders2.36%
Institutions37.65%
Short Interest
Short Ratio3.9d
Short % Float8.25%
Short % Out.8.06%
Shares Short2.15M
Short (prev mo.)1.83M
Technical
SMA 507.235 (-1.3%)
SMA 2005.860 (+21.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)573.43K
Avg Vol (10d)553.46K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—